Hormonal
Bariatric surgery (specifically Roux-en-Y gastric bypass) is the only current obesity treatment effective for long-term weight loss and resolution of comorbidities, whereas non-surgical lifestyle and pharmacological interventions typically produce modest, poorly sustained weight loss.
If you have severe obesity, lifestyle changes and current medications rarely lead to lasting weight loss. Bariatric surgery is currently the only intervention proven to sustain significant weight loss and resolve related health issues long-term. Discuss surgical options with a specialist if you qualify, as non-surgical methods often fail to maintain results.
bariatric–metabolic surgery is the only current treatment for obesity that is effective in the long term. Lifestyle modification and current pharmacological approaches are generally associated with modest (average 5 kg) weight loss that is poorly sustained in a majority of patients.
Why this rating
Supported by large prospective studies (Swedish Obese Subjects Trial) and meta-analyses of 136 studies.
Source
Recent advances in clinical practice challenges and opportunities in the management of obesity
Andrés Acosta et al. · Gut · 2014
DOI 10.1136/gutjnl-2013-306235
More from this paper
- Roux-en-Y gastric bypass (RYGB) induces weight loss and metabolic improvements through complex neurohormonal mechanisms (incretins, vagal signaling, microbiome shifts) rather than solely through mechanical restriction or malabsorption.Good
- Newer FDA-approved pharmacological interventions (Lorcaserin, Phentermine-Topiramate ER) produce greater weight loss than older medications but remain less effective than bariatric surgery and carry risks of central nervous system and cardiovascular adverse effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →